Account

Search results for: orphan drugs

Orphan status higher prices in the UK

Beyond the regulatory level, a well-recognised challenge for companies launching drugs in orphan dis...

Read more
Orphan drug status benefit

The purpose of this study is to compare the assessments of orphan and non-orphan drugs by NICE.

Read more
Latest survey shows disparities in access

The study, compiled by IQVIA, covers 160 drugs, including 41 oncology drugs and 57 orphan drugs whic...

Read more
The JCA is here – are you generating the right e...

Five success pillars — your JCA evidence-generation checklist  From 12th January 2025, the Eu...

Read more
EU Pharma Package Overhaul: Council Agreement Ushe...

Executive Summary  What Has Changed in the Pharma Package?  The Council’s agreed text on the Pha...

Read more
Joint Scientific Consultations: When, Why, and How...

The increasing complexity of bringing innovative therapies to market across various jurisdictions pr...

Read more
Unlocking Access: The Role of Patient Engagement i...

AUTHORS: ​Joyce Atim, Rahul Vadehra​ Rare diseases have a significant impact on people worldwide...

Read more
WODC Europe 2024: Comparing And Contrasting Early ...

AUTHORS: Amy Boyers, Solen Monteil, Mariam Bibi OBJECTIVES  Early Access Programmes (EAPs) prov...

Read more
Can Real-World Evidence overcome uncertainty in Ra...

We examine how real-world evidence strategies help address uncertainties in rare disease treatments ...

Read more
How to integrate Market Access strategy with evide...

Introduction What is the secret to a successful drug launch? One crucial factor is establishing a cr...

Read more
Older
Newer

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch